JP5839467B2 - 癌を治療するための方法 - Google Patents
癌を治療するための方法 Download PDFInfo
- Publication number
- JP5839467B2 JP5839467B2 JP2011552473A JP2011552473A JP5839467B2 JP 5839467 B2 JP5839467 B2 JP 5839467B2 JP 2011552473 A JP2011552473 A JP 2011552473A JP 2011552473 A JP2011552473 A JP 2011552473A JP 5839467 B2 JP5839467 B2 JP 5839467B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- gingival
- use according
- cells
- fibroblasts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 27
- 201000011510 cancer Diseases 0.000 title claims description 21
- 238000000034 method Methods 0.000 title description 12
- 210000002950 fibroblast Anatomy 0.000 claims description 60
- 210000004027 cell Anatomy 0.000 claims description 51
- 239000003636 conditioned culture medium Substances 0.000 claims description 28
- 206010027476 Metastases Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 206010064390 Tumour invasion Diseases 0.000 claims description 5
- 230000009400 cancer invasion Effects 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000009545 invasion Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 208000037819 metastatic cancer Diseases 0.000 claims description 3
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 201000010918 connective tissue cancer Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 26
- 239000002609 medium Substances 0.000 description 17
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 15
- 239000012894 fetal calf serum Substances 0.000 description 15
- 230000008595 infiltration Effects 0.000 description 11
- 238000001764 infiltration Methods 0.000 description 11
- 239000000284 extract Substances 0.000 description 7
- 230000003211 malignant effect Effects 0.000 description 7
- 230000004709 cell invasion Effects 0.000 description 6
- 102000012422 Collagen Type I Human genes 0.000 description 5
- 108010022452 Collagen Type I Proteins 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 210000001626 skin fibroblast Anatomy 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 102000004954 Biglycan Human genes 0.000 description 1
- 108090001138 Biglycan Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 102000007000 Tenascin Human genes 0.000 description 1
- 108010008125 Tenascin Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000006230 breast fibrosarcoma Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- JOSBTZULDGZZRE-UHFFFAOYSA-N elanine Natural products CCC(C)C(=O)OC1C2CC3C1C(O)(CC2OC)C4(O)C(OC)C5C6(COC(=O)c7ccccc7N8C(=O)CC(C)C8=O)CCC(OC)C35C4N(CC)C6 JOSBTZULDGZZRE-UHFFFAOYSA-N 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 210000000651 myofibroblast Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 108010047805 oxytalan Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/33—Fibroblasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0632—Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/09—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells
- C12N2502/097—Coculture with; Conditioned medium produced by epidermal cells, skin cells, oral mucosa cells oral mucosa cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
本明細書中で意図する場合、発明に従って予防又は治療される癌は任意のタイプの癌とすることができる。好ましくは、転移性癌又は転移を形成する傾向のある癌である。従って、本発明の方法において、好ましくは癌細胞の浸潤が抑制される。さらに、癌が腫瘍、特に固形腫瘍を形成する場合、本発明の方法は、好ましくは腫瘍浸潤を予防又は治療する。言い換えれば、本発明の方法は、好ましくは癌の転移を予防又は治療する。
-個体から歯肉線維芽細胞を採取する工程;
-歯肉線維芽細胞を培養する工程;
-培養された歯肉線維芽細胞から歯肉線維芽細胞由来の生成物を得る工程;
-歯肉線維芽細胞由来の生成物を個体へ投与する工程、
を含んでなる。
1.細胞培養
マウス乳癌の4T1株化細胞(M4T1)又はヒト線維肉腫のHT1080株化細胞から悪性細胞を得た。
基底層抽出物(R&D system ref: 3455-96-K)又はI型コラーゲン(R&D system ref: 3457-96-K)(50μl)の細胞浸潤キット中で、60000個の4T1又はHT1080細胞を10%FCSで培養し、任意に上記の通り得られた条件培地(150μl)と接触させた。製造者説明書に従って、24時間後に細胞浸潤を測定した。
1.ヒト歯肉線維芽細胞由来の条件培地は、基底層抽出物上の悪性細胞による細胞浸潤を抑制する。
同様の結果が、HT1080及びM4T1悪性細胞に関して得られた(図1及び2)。
同様の結果が、HT1080及びM4T1悪性細胞に関して得られた(図3及び4)。
Claims (10)
- 癌細胞の侵襲の抑制による癌の予防又は治療のための医薬の製造のための、歯肉線維芽細胞由来の生成物の使用であって、
該歯肉線維芽細胞由来の生成物が、歯肉線維芽細胞の全細胞、歯肉線維芽細胞の培養物、及び歯肉線維芽細胞の条件培地から成る群から選択される、使用。 - 腫瘍浸潤の予防又は治療のための医薬の製造のための、請求項1に記載の使用。
- 前記歯肉線維芽細胞由来の生成物が局所注射によって投与される、請求項1又は2に記載の使用。
- 前記歯肉線維芽細胞由来の生成物が、経口経路、皮下経路、静脈内経路、及び筋肉内経路から成る群から選択される経路によって投与される、請求項1又は2に記載の使用。
- 前記歯肉線維芽細胞由来の生成物が、個体から採取された歯肉線維芽細胞から得られる、請求項1〜4のいずれか1項に記載の使用。
- 前記歯肉線維芽細胞由来の生成物が、歯肉線維芽細胞の条件培地である、請求項1〜5のいずれか1項に記載の使用。
- 前記癌が、転移性癌又は転移を形成する傾向のある癌である、請求項1〜6のいずれか1項に記載の使用。
- 前記癌が、固形腫瘍である、請求項1〜7のいずれか1項に記載の使用。
- 前記癌の転移が、予防又は治療される、請求項7に記載の使用。
- 前記癌が、結合組織の癌である、請求項1〜9のいずれか1項に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15803709P | 2009-03-06 | 2009-03-06 | |
US61/158,037 | 2009-03-06 | ||
PCT/EP2010/052901 WO2010100282A1 (en) | 2009-03-06 | 2010-03-08 | Method for treating cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012519670A JP2012519670A (ja) | 2012-08-30 |
JP5839467B2 true JP5839467B2 (ja) | 2016-01-06 |
Family
ID=42101672
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011552473A Active JP5839467B2 (ja) | 2009-03-06 | 2010-03-08 | 癌を治療するための方法 |
Country Status (5)
Country | Link |
---|---|
US (3) | US20120100111A1 (ja) |
EP (1) | EP2403508B1 (ja) |
JP (1) | JP5839467B2 (ja) |
CA (1) | CA2754635C (ja) |
WO (1) | WO2010100282A1 (ja) |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5149691A (en) * | 1991-03-12 | 1992-09-22 | Creative Biomolecules, Inc. | Issue repair and regeneration through the use of platelet derived growth factor (pdgf) in combination with dexamethasone |
JP3512111B2 (ja) * | 1992-05-22 | 2004-03-29 | モンタナ ステイト ユニバーシティ | 多重付着分子に対する特異性を有する抗体 |
DK0746613T3 (da) * | 1994-03-08 | 2006-09-25 | Sloan Kettering Inst Cancer | Rekombinante humaniserede antistoffer mod FB5 |
US5830640A (en) * | 1995-03-07 | 1998-11-03 | George Washington University | Determining invasiveness of prostatic adenocarcinoma |
US6251882B1 (en) * | 1998-06-29 | 2001-06-26 | Parker Hughes Institute | Alkyl ketones as potent anti-cancer agents |
IL125698A (en) * | 1998-08-07 | 2007-03-08 | Hadasit Med Res Service | Use of molecules associated with protease activated receptors for the preparation of pharmaceutical compositions and pharmaceutical compositions comprising them |
EP1174129A1 (en) * | 2000-07-17 | 2002-01-23 | Zenner, Hans Peter, Prof. Dr. med. | Use of a matrix-metalloprotease inhibitor for the treatment of cancer |
CN1622992A (zh) * | 2002-01-23 | 2005-06-01 | 马蒂亚斯·拉特 | 合成肽及其用于预防和治疗癌症侵袭和转移的用途 |
FR2872431B1 (fr) * | 2004-07-02 | 2007-07-20 | Univ Rene Descartes Paris V Et | Utilisation de fibroplastes gingivaux en therapie cellulaire vasculaire |
CA2660434C (en) * | 2006-08-10 | 2016-09-27 | Universite Rene Descartes-Paris V | Use of gingival fibroblasts for treating a skin wound |
KR101325374B1 (ko) * | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 신체 기능의 회복에 유용한 경구 또는 경장 조성물 |
-
2010
- 2010-03-08 JP JP2011552473A patent/JP5839467B2/ja active Active
- 2010-03-08 WO PCT/EP2010/052901 patent/WO2010100282A1/en active Application Filing
- 2010-03-08 EP EP10706679.7A patent/EP2403508B1/en active Active
- 2010-03-08 US US13/255,039 patent/US20120100111A1/en not_active Abandoned
- 2010-03-08 CA CA2754635A patent/CA2754635C/en active Active
-
2016
- 2016-02-17 US US15/046,190 patent/US20160158290A1/en not_active Abandoned
-
2017
- 2017-10-12 US US15/782,345 patent/US20180028571A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20120100111A1 (en) | 2012-04-26 |
US20160158290A1 (en) | 2016-06-09 |
JP2012519670A (ja) | 2012-08-30 |
EP2403508A1 (en) | 2012-01-11 |
CA2754635C (en) | 2018-06-19 |
WO2010100282A1 (en) | 2010-09-10 |
CA2754635A1 (en) | 2010-09-10 |
EP2403508B1 (en) | 2015-10-28 |
US20180028571A1 (en) | 2018-02-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Iwanowycz et al. | Emodin inhibits breast cancer growth by blocking the tumor-promoting feedforward loop between cancer cells and macrophages | |
Wu et al. | Bone marrow‐derived mesenchymal stem cell attenuates skin fibrosis development in mice | |
Niada et al. | Adipose-derived stromal cell secretome reduces TNFα-induced hypertrophy and catabolic markers in primary human articular chondrocytes | |
CA2560058A1 (en) | A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis | |
JP2016505539A5 (ja) | ||
Acero et al. | CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models | |
WO2006108718B1 (en) | Micro rna | |
Chen et al. | Sphingosine 1-phosphate promotes mesenchymal stem cell-mediated cardioprotection against myocardial infarction via ERK1/2-MMP-9 and Akt signaling axis | |
IL166657A0 (en) | Pharmaceutical compositions containing an agent effective to reduce the effective amount of clusterin | |
He et al. | Resistin promotes cardiac homing of mesenchymal stem cells and functional recovery after myocardial ischemia-reperfusion via the ERK1/2-MMP-9 pathway | |
WO2020146521A3 (en) | Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use | |
EP3233086B1 (en) | Suppression of neointimal formation following vascular surgery using cdk8 inhibitors | |
Li et al. | Mesenchymal stem cells in gastric cancer: vicious but hopeful | |
Ye et al. | Characteristic and fate determination of adipose precursors during adipose tissue remodeling | |
JP5839467B2 (ja) | 癌を治療するための方法 | |
WO2005009217A3 (en) | Diagnosis of pre-cancerous conditions using pcdgf agents | |
Wang et al. | Dual protective role of velutin against articular cartilage degeneration and subchondral bone loss via the p38 signaling pathway in murine osteoarthritis | |
Baird | Mesenchymal stem cells: how can we realize their therapeutic potential in cancer therapy? | |
US20230398190A1 (en) | Compositions and methods for treating solid cancer | |
WO2013166438A1 (en) | Substrates and inhibitors of prolyl oligopeptidase and fibroblast activation protein and methods of use | |
WO2005040147A1 (ja) | 抗腫瘍剤 | |
Roomi et al. | A nutrient mixture reduced tumor growth of SK-UT-1 human leiomyosarcoma cells in vivo and in vitro by inhibiting MMPs and inducing apoptosis | |
ES2347627A1 (es) | Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales. | |
RU2009137770A (ru) | Внутрипузырное введение апазиквона после трансуретральной резекции при лечении рака | |
Pulavendran et al. | Antioxidant and Anti-Inflammatory Action of Stem Cells in Cardiac Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20121120 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20121120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130220 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140415 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140714 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140722 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141015 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150310 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150609 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20151006 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20151105 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5839467 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |